Johnson & Johnson
Researches, develops, manufactures and sells pharmaceuticals and medical devices across oncology, immunology, surgery, orthopaedics, cardiovascular care and vision worldwide.
As of Jul 17, 2026
Executive summary
Johnson & Johnson is a multinational healthcare company operating across pharmaceuticals, medical devices, and consumer health. The stock trades with a neutral technical bias at $253.04, having gained 7.6% over the past month and 57.4% over the past year. With a market capitalisation of $602 billion, JNJ reflects the scale and diversification of one of the world's largest healthcare businesses.
Price history
As of Jul 17, 2026
Performance
+1.23%
-1.53%
+7.59%
+8.52%
+23.64%
+57.42%
As of Jul 17, 2026
Technical indicators
- 54.5
- -1.52Bearish
- 50: 238.31 · 200: 221.1Bullish
- $227.50 / $269.43
Technical Bias
Johnson & Johnson's technical picture is split three ways right now. The 50-day moving average sits above the 200-day, a bullish structural signal, while the MACD reads bearish at minus 1.52. RSI at 54.5 sits squarely neutral, showing no overbought or oversold pressure. This is a derived technical read, not a recommendation.
A transparent read of the indicators below — not a prediction or recommendation.
As of Jul 17, 2026
Fundamentals
- $602B
- 28.67
- $8.72
- 21.48%
- +6.6%
- $19.7B
- 0.24
- $158.80 – $269.43
- 2.17%
- Aug 25, 2026
- —
As of Jul 18, 2026
Upcoming catalysts
- Ex-dividend date
As of Jul 18, 2026
Latest news
As of Jul 18, 2026
Short-term outlook
Johnson & Johnson has climbed 7.6% over the past month and sits above both its 50-day and 200-day averages, keeping the broader trend on a bullish footing. That said, the MACD's bearish tilt alongside a neutral RSI suggests momentum may be cooling near-term. With resistance up at $269.43 and support down at $227.50, the stock looks set to trade within this range over the coming weeks.
Medium-term outlook
Johnson & Johnson continues to grow its top line at a steady 6.6% year-on-year pace, backed by a healthy 21.5% profit margin that points to solid operational efficiency. With a P/E of 28.67, the stock trades on a fairly rich rating, while its 2.2% dividend yield offers some income support. Technically, the picture is neutral, suggesting the next few quarters may see the shares consolidate rather than trend strongly either way.
Key risks
- Johnson & Johnson trades at a P/E of 28.67, which is a rich valuation that leaves little room for disappointment if growth slows.
- The stock recently fell despite a strong Q2 beat and a higher 2026 outlook, showing that even solid results aren't guaranteed to move shares higher.
- Shares sit close to their 52-week high of $269.43, which can make further upside harder to come by after such a run.
- As a Dividend King often grouped with income-focused portfolios, J&J's appeal may be sensitive to shifts in interest rates and how its yield compares with alternatives like Treasuries.
About Johnson & Johnson
Johnson & Johnson is one of the world's largest healthcare companies, listed on the NYSE under the ticker JNJ. Classified within the Healthcare sector and the Drug Manufacturers - General industry, the company holds a substantial position in the pharmaceutical space, reflected in its market capitalisation of $602B. This scale places Johnson & Johnson among the major players that investors often watch as a bellwether for the broader healthcare industry.
Johnson & Johnson's key figures give a snapshot of how the market currently values the business. A price-to-earnings ratio of 28.67 shows what investors are paying relative to the company's earnings, while a dividend yield of +2.2% reflects the portion of returns paid out to shareholders. Together, these metrics offer a useful starting point for understanding how JNJ is positioned within the healthcare sector today.
AI-assisted research for informational purposes only — not investment advice. Figures are sourced from third-party market data and may be delayed. Do your own research before trading. Your capital is at risk.